|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of high-resolution ultrasound and MR-enterography in patients with inflammatory bowel disease显示文摘AIM:To compare the results of high-resolution ultrasound(HR-US) and magnetic resonance enterography(MRE) examinations in patients with inflammatory bowel disease(IBD).METHODS:The reports of 250 consecutive cases with known IBD,who had an MRE and HR-US examination,were retrospectively analyzed.Using a patient-based approach we evaluated morphological disease features such as affected bowel wall,stenosis,abscess and fistula.The comparison between the two modalities was based on the hypothesis,that any pathological change described in any imaging modality was a true finding,as no further standard of reference was available for complete assessment.RESULTS:Two hundred and fifty examinations representing 207 different patients were evaluated.Both modalities assessed similar bowel wall changes in 65% of the examinations,with more US findings in 11% and more MRE findings in 15%.When the reports were analyzed with regard to 'bowel wall inflammation',US reported more findings in 2%,while MRE reported more findings in 53%.Stenoses were assessed to be identical in 8%,while US found more in 3% and MRE in 29%(P < 0.01).For abscess detection,US showed more findings in 2%(n = 4) while MRE detected more in 6%(n = 16).US detected more fistulas in 1%(n = 2),while MRE detected more in 13%(n = 32)(P < 0.001).The most common reason for no detected pathology by US was a difficult to assess anatomical region(lesser pelvis,n = 72).CONCLUSION:US can miss clinically relevant pathological changes in patients with IBD mostly due to difficulty in assessing certain anatomical regions. | Andreas G Schreyer Cynthia Menzel Chris Friedrich Florian Poschenrieder Lukas Egger Christian Dornia Gabriela Schill Lena M Dendl Doris Schacherer Christl Girlich Ernst-Michael Jung | 2011 | World Journal of Gastroenterology2011，17，8： | 7 |
| 2 | Dynamic magnetic resonance defecography in 10 asymptomatic volunteers显示文摘AIM: Evaluation of the wide range of normal findings in asymptomatic women undergoing dynamic magnetic resonance (MR) defecography. METHODS: MR defecography of 10 healthy female volunteers (median age: 31 years) without previous pregnancies or history of surgery were evaluated. The rectum was filled with 180 mL gadolinium ultrasound gel mixture. MR defecography was performed in the supine position. The pelvic floor was visualized with a dynamic T2-weighted sagittal plane where all relevant pelvic floor organs were acquired during defecation. The volunteers were instructed to relax and then to perform straining maneuvers to empty the rectum. The pubococcygeal line (PCGL) was used as the line of reference. The movement of pelvic floor organs was measured as the vertical distance to this reference line. Data were recorded in the resting position as well as during the defecation process with maximal straining. Examinations were performed and evaluated by two experienced abdominal radiologists without knowledge of patient history. RESULTS: Average position of the anorectal junction was located at -5.3 mm at rest and -29.9 mm during straining. The anorectal angle widened significantly from 93° at rest to 109° during defecation. A rectocele was diagnosed in eight out of 10 volunteers showing an average diameter of 25.9 mm. The bladder base was located at a position of +23 mm at rest and descended to -8.1 mm during defecation in relation to the PCGL. The bladder base moved below the PCGL in six out of 10 volunteers, which was formally defined as a cystocele. The uterocervical junction was located at an average level of +43.1 mm at rest and at +7.9 mm during straining. The uterocervical junction of three volunteers fell below the PCGL; described formally as uterocervical prolapse. CONCLUSION: Based on the range of standard values in asymptomatic volunteers, MR defecography values for pathological changes have to be re-evaluated. | Andreas G Schreyer Christian Paetzel Alois Fürst Lena M Dendl Elisabeth Hutzel René Müller-Wille Philipp Wiggermann Stephan Schleder Christian Stroszczynski Patrick Hoffstetter | 2012 | World Journal of Gastroenterology2012，18，46： | 7 |
| 3 | Recent trends in liver transplantation for alcoholic liver disease in the United States显示文摘AIM To examine temporal changes in the indications for liver transplantation(LT) and characteristics of patients transplanted for alcoholic liver disease(ALD).METHODS We performed a retrospective cohort analysis of trends in the indication for LT using the United Network for Organ Sharing(UNOS) database between 2002 and 2015. Patients were grouped by etiology of the liver disease and characteristics were compared using χ~2 and t-tests. Time series analysis was used identifying any year with a significant change in the number of transplants per year for ALD, and before and after eras were modeled using a general linear model. Subgroup analysis of recipients with ALD was performed by age group, gender, UNOS region and etiology(alcoholic cirrhosis, alcoholic hepatitis and hepatitis C-alcoholic cirrhosis dual listing).RESULTS Of 74216 liver transplant recipients, ALD(n = 9400, 12.7%) was the third leading indication for transplant after hepatitis C and hepatocellular carcinoma. Transplants for ALD, increased from 12.8%(553) in 2002 to 16.5%(1020) in 2015. Time series analysis indicated a significant increase in the number of transplants per year for ALD in 2013(P = 0.03). There were a stable number of transplants per year between 2002 and 2012(linear coefficient 3, 95%CI:-4.6, 11.2) an increase of 177 per year between 2013 and 2015(95%CI: 119, 234). This increase was significant for all age groups except those 71-83 years old, was observed for both genders, and was incompletely explained by a decrease in transplants for hepatitis C and ALD dual listing. All UNOS regions except region 9 saw an increase in the mean number of transplants per year when comparing eras, and this increase was significant in regions 2, 3, 4, 5, 6, 8, 10 and 11.CONCLUSION There has been a dramatic increase in the number of transplants for ALD starting in 2013. | Catherine E Kling James D Perkins Robert L Carithers Dennis M Donovan Lena Sibulesky | 2017 | World Journal of Hepatology2017，9，36： | 6 |
| 4 | Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis显示文摘The risk of thromboembolism is increased in inflammatory bowel disease and its symptoms may be overlooked. Furthermore, its treatment can be complex and is not without complications. We describe a case of an adolescent boy who developed a cerebral sinus venous thrombosis during a relapse of his ulcerative colitis and who, while on treatment with heparin, developed heparin-induced thrombocytopenia (HIT). The treatment was then switched to fondaparinux, a synthetic and selective inhibitor of activated factor . | Gudrun Scheving Thorsteinsson Maria Magnussson Lena M Hallberg Nils Gunnar Wahlgren Fredrik Lindgren Petter Malmborg Thomas H Casswall | 2008 | World Journal of Gastroenterology2008，14，28： | 4 |
| 5 | Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4^(-/-) mouse model显示文摘AIM: To study the interleukin-1(IL-1) pathway as a therapeutic target for liver fibrosis in vitro and in vivo using the ATP-binding cassette transporter b4^(-/-)(Abcb4^(-/-)) mouse model.METHODS: Female and male Abcb4^(-/-) mice from 6 to 13 mo of age were analysed for the degree of cholestasis(liver serum tests), extent of liver fibrosis(hydroxyproline content and Sirius red staining) and tissue-specific activation of signalling pathways such as the IL-1 pathway [quantitative polymerase chain reaction(q PCR)]. For in vivo experiments, murine hepatic stellate cells(HSCs) were isolated via pronasecollagenase perfusion followed by density gradient centrifugation using female mice. Murine HSCs were stimulated with up to 1 ng/m L IL-1β with or without 2.5 μg/m L Anakinra, an IL-1 receptor antagonist, respectively. The proliferation of murine HSCs was assessed via the Brd U assay. The toxicity of Anakinra was evaluated via the fluorescein diacetate hydrolysis(FDH) assay. In vivo 8-wk-old Abcb4^(-/-) mice with an already fully established hepatic phenotype were treated with Anakinra(1 mg/kg body-weight daily intraperitoneally) or vehicle and liver injury and liver fibrosis were evaluated via serum tests, q PCR, hydroxyproline content and Sirius red staining. RESULTS: Liver fibrosis was less pronounced in males than in female Abcb4^(-/-) animals as defined by a lower hydroxyproline content(274 ± 64 μg/g vs 436 ± 80 μg/g liver, respectively; n = 13-15; P < 0.001; MannWhitney U-test) and lower m RNA expression of the profibrogenic tissue inhibitor of metalloproteinase-1(TIMP)(1 ± 0.41 vs 0.66 ± 0.33 fold, respectively; n = 13-15; P < 0.05; Mann-Whitney U-test). Reduced liver fibrosis was associated with significantly lower levels of F4/80 m RNA expression(1 ± 0.28 vs 0.71 ± 0.41 fold, respectively; n = 12-15; P < 0.05; Mann-Whitney U-test) and significantly lower IL-1β m RNA expression levels(1 ± 0.38 vs 0.44 ± 0.26 fold, respectively; n = 13-15; P < 0.001; Mann-Whitney U-test). No gender differences in the serum liver parameters [bilirubin; alanine aminotransferase(ALT); aspartate aminotransferase and alkaline phosphatase(AP)] were found. In vitro, the administration of IL-1β resulted in a significant increase in HSC proliferation [0.94 ± 0.72 arbitrary units(A.U.) in untreated controls, 1.12 ± 0.80 A.U. at an IL-1β concentration of 0.1 ng/m L and 1.18 ± 0.73 A.U. at an IL-1β concentration of 1 ng/m L in samples from n = 6 donor animals; P < 0.001; analyses of variance(ANOVA)]. Proliferation was reduced significantly by the addition of 2.5 μg/m L Anakinra(0.81 ± 0.60 A.U. in untreated controls, 0.92 ± 0.68 A.U. at an IL-1β concentration of 0.1 ng/m L, and 0.91 ± 0.69 A.U. at an IL-1β concentration of 1 ng/m L; in samples from n = 6 donor animals; P < 0.001; ANOVA) suggesting an anti-proliferative effect of this clinically approved IL-1 receptor antagonist. The FDH assay showed this dose to be non-toxic in HSCs. In vivo, Anakinra had no effect on the hepatic hydroxyprolinecontent, liver serum tests(ALT and AP) and profibrotic(collagen 1α1, collagen 1α2, transforming growth factor-β, and TIMP-1) and anti-fibrotic [matrix metalloproteinase 2(MMP2), MMP9 and MMP13 ] gene expression after 4 wk of treatment. Furthermore, the hepatic IL-1β and F4/80 m RNA expression levels were unaffected by Anakinra treatment.CONCLUSION: IL-1β expression is associated with the degree of liver fibrosis in Abcb4^(-/-) mice and promotes HSC proliferation. IL-1 antagonism shows antifibrotic effects in vitro but not in Abcb4^(-/-) mice. | Florian P Reiter Ralf Wimmer Lena Wottke Renate Artmann Jutta M Nagel Manuel O Carranza Doris Mayr Christian Rust Peter Fickert Michael Trauner Alexander L Gerbes Simon Hohenester Gerald U Denk | 2016 | World Journal of Hepatology2016，8，8： | 3 |
| 6 | Emergence of novel strains of avian infectious bronchitis virus in Sweden显示文摘 | Shahid Hussain Abro Lena H.M. Renstr?m Karin Ullman Mats Isaksson Siamak Zohari Désirée S. Jansson Sándor Belák Claudia Baule | 2011 | Veterinary Microbiology (-)2011，，2： | 2 |
| 7 | Fecal calprotectin one year after ileocaecal resection for Crohn’s disease — A comparison with findings at ileocolonoscopy显示文摘 | Anders Lasson Hans Strid Lena ?hman Stefan Isaksson Mikael Olsson Britt Rydstr?m Kjell-Arne Ung Per-Ove Stotzer | 2013 | Journal of Crohn’s and Colitis2013，，： | 2 |
| 8 | Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford显示文摘BACKGROUND Vedolizumab(VDZ),a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis(UC)patients.AIM To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission.METHODS A retrospective review of Australian and Oxford,United Kingdom data for UC patients.Clinical response at 3 mo,endoscopic remission at 6 mo and clinical remission at 3,6 and 12 mo were assessed.Cox regression models and Kaplan Meier curves were performed to assess the time to remission,time to failure and the covariates influencing them.Safety outcomes were recorded.RESULTS Three hundred and three UC patients from 14 centres in Australia and United Kingdom,[60%n=182,anti-TNF naïve]were included.The clinical response was 79%at 3 mo with more Australian patients achieving clinical response compared to Oxford(83%vs 70%P=0.01).Clinical remission for all patients was 56%,62%and 60%at 3,6 and 12 mo respectively.Anti-TNF naive patients were more likely to achieve remission than exposed patients at all the time points(3 mo 66%vs 40%P<0.001,6 mo 73%vs 46%P<0.001,12 mo 66%vs 51%P=0.03).More Australian patients achieved endoscopic remission at 6 mo compared to Oxford(69%vs 43%P=0.01).On multi-variate analysis,anti-TNF naïve patients were 1.8(95%CI:1.3-2.3)times more likely to achieve remission than anti-TNF exposed(P<0.001).32 patients(11%)had colectomy by 12 mo.CONCLUSION VDZ was safe and effective with 60%of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome. | Samba Siva Reddy Pulusu Ashish Srinivasan Krupa Krishnaprasad Daniel Cheng Jakob Begun CharlotteKeung Daniel Van Langenberg Lena Thin Tamara Mogilevski Peter De Cruz Graham Radford-Smith Emma Flanagan Sally Bell Soleiman Kashkooli Miles Sparrow Simon Ghaly Peter Bampton Elise Sawyer Susan Connor Quart-ul-ain Rizvi Jane M Andrews Gillian Mahy Paola Chivers Simon Travis Ian Craig Lawrance | 2020 | World Journal of Gastroenterology2020，26，30： | 2 |
| 9 | PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals显示文摘 | Maria Antonella Burza Carlo Pirazzi Cristina Maglio Kajsa Sj?holm Rosellina Margherita Mancina Per-Arne Svensson Peter Jacobson Martin Adiels Marco Giorgio Baroni Jan Borén Stefano Ginanni Corradini Tiziana Montalcini Lars Sj?str?m Lena Mariana Susann Car | 2012 | Digestive and Liver Disease2012，，12： | 2 |
| 10 | MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment 显示文摘 | Bonfrate L Altomare DF Di Lena M | 2013 | J Gastrointestin Liver Dis2013，22，3： | 1 |
| 11 | Adjuvant vinorel- bine plus cisplatin versus observation in patients with com- pletely resected stage Ib-IIIa non-small-cell lung cancer (adju- vant navelbine international trialist association ): a randomised controlled trial显示文摘 | Douillard JY Rosell R De Lena M | 2006 | Lancet Oncol2006，7，9： | 1 |
| 12 | Chemical fractionation of Cadmium, Copper,Nicke,and Zinc in contaminated soils显示文摘 | LENA Q M GADE N R | 1997 | J Environ Quality1997，26，1： | 1 |
| 13 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely reseeted stage IB-IIIA non-small-cell lung cancer( Adjuvant Navelbine International Trialist Association ) : a randomised controlled trial 显示文摘 | Douillard JY Rosell R De Lena M | 2006 | Lancet Oncol2006，7，9： | 1 |
| 14 | Adjuvant Vinorelbine plus Cisplatin versus observation in patients with completely resected stage Ⅰ B-Ⅲ A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ) : A randomised controlled trial显示文摘 | Douillard JY Rosell R De Lena M | 2006 | Lancet Oncol2006，7，9： | 1 |
| 15 | Nitrogen uptake in relation to excess supply and its effects on the lichens Evernia prunastri (L.) Ach and Xanthoria parietina (L.) Th. Fr.显示文摘 | Gisela Gaio-Oliveira Lena Dahlman Kristin Palmqvist Maria Amélia Martins-Lou??o Cristina Máguas | 2005 | Planta2005，，5： | 1 |
| 16 | Decreasing Time-Trends of Colorectal Cancer in a Large Cohort of Patients With Inflammatory Bowel Disease显示文摘 | Sverre S?derlund Lena Brandt Annika Lapidus Per Karlén Olle Brostr?m Robert L?fberg Anders Ekbom Johan Askling | 2009 | Gastroenterology2009，，5： | 1 |
| 17 | A ran- domised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy fol- lowed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 显示文摘 | De Placido S De Laurentiis M De Lena M | 2005 | Br J Cancer2005，92，3： | 1 |
| 18 | Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association):a randomised controlled trial显示文摘 | Douillard JY Rosell R De Lena M | 2006 | The Lancet Oncology2006，7，9： | 1 |
| 19 | miR-203 represses 'sternness' by repressing DeltaNp63 显示文摘 | A M Lena R Shalom-Feuerstein P Rivetti di Val Cervo | 2008 | Cell Death Differ2008，15，7： | 1 |
| 20 | Lung macrophages and dendritic cells express HLA - G molecules in pulmonary diseases 显示文摘 | Pangault C Le Friec G Caulet - Maugendre S Lena H Amiot L Guilloux V Onno M Fauchet R | 2002 | Hum Immunol2002，63，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员